BR9907855A - Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animal - Google Patents

Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animal

Info

Publication number
BR9907855A
BR9907855A BR9907855-4A BR9907855A BR9907855A BR 9907855 A BR9907855 A BR 9907855A BR 9907855 A BR9907855 A BR 9907855A BR 9907855 A BR9907855 A BR 9907855A
Authority
BR
Brazil
Prior art keywords
protein
conjugate
particle
modified hepatitis
core
Prior art date
Application number
BR9907855-4A
Other languages
English (en)
Inventor
Ashley J Birkett
Original Assignee
Immune Complex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Complex Corp filed Critical Immune Complex Corp
Publication of BR9907855A publication Critical patent/BR9907855A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/795—Composed of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/894—Manufacture, treatment, or detection of nanostructure having step or means utilizing biological growth
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine

Abstract

"CONJUGADO DE PROTEìNA DE NúCLEO DE HEPATITE B ESTRATEGICAMENTE MODIFICADA, PARTìCULA DE PROTEìNA, CONJUGADO DE PARTìCULAS DE PROTEìNA, CONJUGADO DE PROTEìNA DE FUSãO IMUNOGêNICA, INóCULO, E, PROCESSO PARA INDUZIR ANTICORPOS EM UM HOSPEDEIRO ANIMAL". Uma proteína de núcleo de hepatite B estrategicamente modificada é descrita, onde um inserto é provido, preferivelmente em uma região imunodominante da proteína de nucleocapsídeo, contendo um resíduo de aminoácido quimicamente reativo. A proteína de núcleo de hepatite B modificada ou suas partículas de proteína de nucleocapsídeo agregadas podem ser pendentemente ligadas a um hapteno para formar um conjugado de nucleocapsídeo modificado. Este conjugado é utilizável na preparação de vacinas ou anticorpos. A proteína de núcleo de hepatite B modificada também pode ser modificada para incluir um epítopo de célula T.
BR9907855-4A 1998-02-12 1999-02-11 Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animal BR9907855A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7453798P 1998-02-12 1998-02-12
PCT/US1999/003055 WO1999040934A1 (en) 1998-02-12 1999-02-11 Strategically modified hepatitis b core proteins and their derivatives

Publications (1)

Publication Number Publication Date
BR9907855A true BR9907855A (pt) 2001-04-24

Family

ID=22120092

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907855-4A BR9907855A (pt) 1998-02-12 1999-02-11 Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animal

Country Status (20)

Country Link
US (1) US6231864B1 (pt)
EP (1) EP1054689B1 (pt)
JP (1) JP4480268B2 (pt)
KR (1) KR100581991B1 (pt)
CN (1) CN100387622C (pt)
AT (1) ATE249240T1 (pt)
AU (1) AU767144B2 (pt)
BR (1) BR9907855A (pt)
CA (1) CA2320488C (pt)
CZ (1) CZ302092B6 (pt)
DE (1) DE69911175T2 (pt)
DK (1) DK1054689T3 (pt)
ES (1) ES2207177T3 (pt)
HK (1) HK1038306A1 (pt)
ID (1) ID26669A (pt)
IL (2) IL137766A0 (pt)
NZ (1) NZ506245A (pt)
PT (1) PT1054689E (pt)
TR (1) TR200002338T2 (pt)
WO (1) WO1999040934A1 (pt)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
RU2245163C2 (ru) 1998-11-30 2005-01-27 Сайтос Байотекнолэджи АГ Композиция (варианты), способ получения не природной упорядоченной и содержащей повторы антигенной матрицы, способ терапевтического лечения и способ иммунизации
US6887464B1 (en) * 1999-02-02 2005-05-03 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
JP2003520568A (ja) * 1999-02-02 2003-07-08 バイオカシェ ファーマシューティカルズ， インコーポレイテッド 高度な抗原提示プラットフォーム
WO2001016174A2 (en) * 1999-08-30 2001-03-08 Rolf Kiessling Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopes of mycobacterial heat shock protein 65
DK1650221T3 (da) 2000-02-23 2012-09-03 Glaxosmithkline Biolog Sa Nye forbindelser
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US6942866B2 (en) * 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
IL157251A0 (en) * 2001-02-05 2004-02-19 Stressgen Biotechnologies Corp Hepatitis b virus treatment
EP1515982A4 (en) 2001-05-09 2005-10-26 Corixa Corp METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
US20030037327A1 (en) * 2001-08-15 2003-02-20 International Business Machines Corporation Run-time rule-based topological installation suite
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US20040146524A1 (en) * 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
EP1425040A2 (en) * 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
BR0213117A (pt) 2001-10-05 2004-09-21 Cytos Biotechnology Ag Conjugados peptìdeo angiotensina-veìculo e seus usos
ES2405405T3 (es) 2001-12-17 2013-05-31 Corixa Corporation Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
WO2003066833A2 (en) * 2002-02-08 2003-08-14 New York University Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies
AU2003215395A1 (en) * 2002-02-21 2003-09-09 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
AU2003213194A1 (en) * 2002-02-21 2003-09-09 Apovia, Inc. IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY
AU2003213168A1 (en) * 2002-02-21 2003-12-19 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
DE60335186D1 (de) * 2002-06-20 2011-01-13 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
CN1668637B (zh) 2002-07-17 2010-05-26 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
EP1523334A2 (en) * 2002-07-18 2005-04-20 Cytos Biotechnology AG Hapten-carrier conjugates and uses thereof
DE60336902D1 (de) * 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
WO2004085635A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag Melan-a peptide analogue-virus-like-particle conjugates
EP1623229A2 (en) * 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
BRPI0411552A (pt) 2003-06-16 2006-08-01 Celltech R & D Inc anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
WO2005011571A2 (en) * 2003-07-30 2005-02-10 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
CN1305527C (zh) * 2003-11-21 2007-03-21 薛平 乙型肝炎治疗疫苗及其制备方法
WO2005068639A2 (en) * 2004-01-20 2005-07-28 Cytos Biotechnology Ag Particle-induced ghrelin immune response
WO2005116270A2 (en) 2004-05-18 2005-12-08 Vical Incorporated Influenza virus vaccine composition and method of use
CA2837748C (en) 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
EP1773303A2 (en) * 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
WO2007117657A2 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
EP2018156B1 (en) * 2006-04-07 2010-03-17 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
WO2008124165A2 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
EA026787B1 (ru) * 2007-08-27 2017-05-31 Общество С Ограниченной Ответственностью "Ниармедик Плюс" Конструкция нуклеиновой кислоты и ее применение для лечения, предотвращения и сдерживания болезни альцгеймера
US20110110973A1 (en) * 2008-02-09 2011-05-12 Sanofi Pasteur Biologics Co. Influenza B Vaccines
CN101423555B (zh) * 2008-11-14 2011-04-20 四川大学华西医院 特异性阻断乙肝病毒组装和复制的膜穿透性多肽
DK2376108T3 (en) 2008-12-09 2017-04-24 Pfizer Vaccines Llc IgE CH3 peptide vaccine
ES2566156T3 (es) 2009-02-02 2016-04-11 Chrontech Pharma Ab Antígeno del núcleo del virus de la hepatitis B (HBcAg) con codones optimizados
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
WO2011013034A1 (en) * 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
RU2538162C2 (ru) 2009-09-03 2015-01-10 Пфайзер Вэксинс ЭлЭлСи Вакцина против pcsk9
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
MX2013013627A (es) 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
WO2013036973A2 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
WO2014031645A1 (en) * 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
EP2948469A4 (en) * 2013-01-23 2016-11-02 Univ Leland Stanford Junior STABILIZED HEPATITIS B CORE POLYPEPTIDE
JP2016517440A (ja) * 2013-03-15 2016-06-16 ブイエルピー バイオテック，インコーポレイテッド パリビズマブエピトープベースのウイルス様粒子
EP2968158A4 (en) 2013-03-15 2017-01-11 VLP Biotech, Inc. Rodent hepadnavirus cores with reduced carrier-specific antigenicity
GB201402890D0 (en) 2014-02-18 2014-04-02 Iqur Ltd Vaccines based on hepatitis B Core antigens
CN104208670B (zh) * 2014-09-09 2017-07-28 韩自勤 一种治疗乙肝的药物组合物
GB201505041D0 (en) * 2015-03-25 2015-05-06 Iqur Ltd Vaccines based on hepatitis B core antigens
CN107383176A (zh) * 2017-05-10 2017-11-24 于学杰 用于对汉滩病毒和汉城病毒引起的肾综合征出血热分型的多肽
MX2019015925A (es) * 2017-06-23 2020-08-06 American Type Culture Collection Atcc Partículas similares a virus que comprenden el antígeno del zika.
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
CN110804097B (zh) * 2019-10-30 2021-02-26 云南沃森生物技术股份有限公司 一种同时制备两种单克隆抗体的方法
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD147855A5 (de) 1978-12-22 1981-04-22 Biogen Nv Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
US4882145A (en) 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5143726A (en) 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB8903313D0 (en) * 1989-02-14 1989-04-05 Wellcome Found Conjugates
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US5840303A (en) * 1991-08-26 1998-11-24 The Scripps Research Foundation Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
WO1998009649A1 (en) * 1996-09-03 1998-03-12 The General Hospital Corporation Inhibition of viral replication

Also Published As

Publication number Publication date
DE69911175D1 (de) 2003-10-16
DK1054689T3 (da) 2004-01-26
IL137766A0 (en) 2001-10-31
IL137766A (en) 2007-12-03
KR20010052165A (ko) 2001-06-25
CA2320488C (en) 2007-03-06
TR200002338T2 (tr) 2002-06-21
CN1300222A (zh) 2001-06-20
EP1054689B1 (en) 2003-09-10
ES2207177T3 (es) 2004-05-16
PT1054689E (pt) 2003-11-28
NZ506245A (en) 2003-08-29
CZ20002819A3 (en) 2001-06-13
AU2675399A (en) 1999-08-30
HK1038306A1 (en) 2002-03-15
AU767144B2 (en) 2003-10-30
US6231864B1 (en) 2001-05-15
WO1999040934A1 (en) 1999-08-19
ID26669A (id) 2001-01-25
JP4480268B2 (ja) 2010-06-16
CN100387622C (zh) 2008-05-14
ATE249240T1 (de) 2003-09-15
KR100581991B1 (ko) 2006-05-23
JP2002509700A (ja) 2002-04-02
EP1054689A4 (en) 2002-02-13
DE69911175T2 (de) 2004-07-29
CA2320488A1 (en) 1999-08-19
EP1054689A1 (en) 2000-11-29
CZ302092B6 (cs) 2010-10-06

Similar Documents

Publication Publication Date Title
BR9907855A (pt) Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animal
Bozett et al. Fatherhood and families in cultural context.
HUP0004327A3 (en) Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions
MY141641A (en) Compositions comprising viruses and methods for concentrating virus preparations
BR9809456A (pt) Molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, processo para produzir umaa partìcula de piv infeccioso de uma ou mais moléculas isoladas de polinucleotìdeo, partìcula isolada de piv infecioso, e, composição imunogênica
DE69731386D1 (de) Verfahren zur behandlung von asthma mit o-desulfatisiertem heparin
GR3030568T3 (en) Inducing cytotoxic t lymphocyte responses.
TR200103581T2 (tr) Graft versus host hastalığı tedavisinde CD20' ye karşı antikorların kullanımı.
Keljo et al. Characterization of Binding of Simian Rotavirus SA‐11 to Cultured Epithelial Cells
BRPI0407636A (pt) meio de cultura de células, linhagem de células animais, métodos para produzir um meio de cultura condicionado, células animais, uma cultura de células animais, vìrus em uma cultura de células animais, ou, de preferência, humanas diplóides dependentes de ancoragem, método para produzir uma vacina, e, população de vìrus
PT96097A (pt) Processo para a preparacao de antigene de toxoplasma gondii bem como de meios de diagnostico, vacinas e anticorpos deles derivados
FI884889A0 (fi) Foerfarande foer framstaellning av en sammansaettning av amfotericin b och kolesterolsulfat.
GB2108527A (en) Non-a non-b hepatitis virus
Hirschman Integrator enzyme hypothesis for replication of hepatitis-B virus
Kumon Morphologically recognizable markers for scanning immunoelectron microscopy: II. An indirect method using T4 and TMV
DE59004731D1 (de) Magnetische Protein-Konjugate, Verfahren zu ihrer Herstellung und ihre Verwendung.
ATE68601T1 (de) Reagenz zur bestimmung durch haemagglutination von antikoerpern gegen bakterien-toxine, verfahren zu ihrer herstellung und verwendung.
DE3888887D1 (de) Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung.
DK0496135T3 (da) Cellefri Mareks sygdomsvirus-vaccine
DE69606856T2 (de) Neue additiv-konzentrate
SE8201128L (sv) Forfarande for reproduktion av virulent treponema pallidum i vevnadsk ultur
Sulitzeanu et al. Soluble Antigens from Rat Liver Connective Tissue.
DE59610968D1 (de) Zellinie und verfahren zur vermehrung von tollwutviren und deren quantitativen nachweis
DE69121933D1 (de) Nukleinsäuren, Antigene und Antikörper betreffend Non-A, Non-B Hepatitis und deren Nachweisreagenzien
Sun et al. Research on the flow around the bluff bodies and flow induced vibrations

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 37, INDEFIRO O PRESENTE PEDIDO COM BASE NO ARTIGO 22 DA LPI VIGENTE.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 14A E 15A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ATE A 21A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.